1. Home
  2. TCMD vs ASMB Comparison

TCMD vs ASMB Comparison

Compare TCMD & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tactile Systems Technology Inc.

TCMD

Tactile Systems Technology Inc.

HOLD

Current Price

$25.55

Market Cap

533.5M

Sector

Health Care

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$27.55

Market Cap

442.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCMD
ASMB
Founded
1995
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
533.5M
442.9M
IPO Year
2016
2010

Fundamental Metrics

Financial Performance
Metric
TCMD
ASMB
Price
$25.55
$27.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$36.00
$44.20
AVG Volume (30 Days)
342.4K
166.2K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
17.14
91.78
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.60
N/A
Revenue Next Year
$9.14
$638.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.42
$14.00
52 Week High
$37.77
$39.71

Technical Indicators

Market Signals
Indicator
TCMD
ASMB
Relative Strength Index (RSI) 56.60 45.76
Support Level $22.78 $26.50
Resistance Level $27.19 $30.58
Average True Range (ATR) 0.96 1.73
MACD 0.25 -0.19
Stochastic Oscillator 80.90 25.97

Price Performance

Historical Comparison
TCMD
ASMB

About TCMD Tactile Systems Technology Inc.

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: